Juber Patel
Overview
Explore the profile of Juber Patel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
678
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jalan M, Brambati A, Shah H, McDermott N, Patel J, Zhu Y, et al.
bioRxiv
. 2025 Mar;
PMID: 40060534
Double-strand breaks (DSBs) are toxic lesions that lead to genome instability. While canonical DSB repair pathways typically operate independently of RNA, emerging evidence suggests that RNA:DNA hybrids and transcripts near...
2.
Gupta A, Gazzo A, Selenica P, Safonov A, Pareja F, da Silva E, et al.
bioRxiv
. 2024 May;
PMID: 38746158
Acquired genetic alterations commonly drive resistance to endocrine and targeted therapies in metastatic breast cancer , however the underlying processes engendering these diverse alterations are largely uncharacterized. To identify the...
3.
Feinberg J, Da Cruz Paula A, da Silva E, Pareja F, Patel J, Zhu Y, et al.
Gynecol Oncol
. 2024 Feb;
185:58-67.
PMID: 38368814
Objective: Adenoid cystic carcinoma (AdCC) of the Bartholin's gland (AdCC-BG) is a very rare gynecologic vulvar malignancy. AdCC-BGs are slow-growing but locally aggressive and are associated with high recurrence rates....
4.
Tsai C, Yang J, Shaverdian N, Patel J, Shepherd A, Eng J, et al.
Lancet
. 2023 Dec;
403(10422):171-182.
PMID: 38104577
Background: Most patients with metastatic cancer eventually develop resistance to systemic therapy, with some having limited disease progression (ie, oligoprogression). We aimed to assess whether stereotactic body radiotherapy (SBRT) targeting...
5.
Ashley C, Selenica P, Patel J, Wu M, Nincevic J, Lakhman Y, et al.
Clin Cancer Res
. 2022 Aug;
29(2):410-421.
PMID: 36007103
Purpose: We sought to determine whether sequencing analysis of circulating cell-free DNA (cfDNA) in patients with prospectively accrued endometrial cancer captures the mutational repertoire of the primary lesion and allows...
6.
Varghese A, Patel J, Janjigian Y, Meng F, Selcuklu S, Iyer G, et al.
JCO Precis Oncol
. 2021 Jul;
5.
PMID: 34250419
Purpose: Fibroblast growth factor receptor (FGFR) 2 alterations, present in 5%-15% of intrahepatic cholangiocarcinomas (IHC), are targets of FGFR-directed therapies. Acquired resistance is common among patients who respond. Biopsies at...
7.
Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, et al.
Nat Commun
. 2021 Jun;
12(1):3770.
PMID: 34145282
Circulating cell-free DNA from blood plasma of cancer patients can be used to non-invasively interrogate somatic tumor alterations. Here we develop MSK-ACCESS (Memorial Sloan Kettering - Analysis of Circulating cfDNA...
8.
Tsui D, Cheng M, Shady M, Yang J, Stephens D, Won H, et al.
Genome Med
. 2021 Jun;
13(1):96.
PMID: 34059130
Background: Cell-free DNA (cfDNA) profiling is increasingly used to guide cancer care, yet mutations are not always identified. The ability to detect somatic mutations in plasma depends on both assay...
9.
Kothari P, Marass F, Yang J, Stewart C, Stephens D, Patel J, et al.
Cancer Med
. 2020 Jul;
9(17):6093-6101.
PMID: 32633890
Purpose: The enucleation rate for retinoblastoma has dropped from over 95% to under 10% in the past 10 years as a result of improvements in therapy. This reduces access to...
10.
Hyman D, Piha-Paul S, Won H, Rodon J, Saura C, Shapiro G, et al.
Nature
. 2019 Feb;
566(7745):E11-E12.
PMID: 30755741
The 'Competing interests' statement of this Article has been updated; please see the accompanying Amendment. The original Article has not been corrected online.